Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-551 Maintenance in Multiple Myeloma
NCT03218163Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2017
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of inebilizumab in multiple myeloma (MM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Sep 2017; status: terminated.
02
Drugs
inebilizumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03218163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03218163.